Signaling Pathways in Inflammation and Anti-inflammatory Therapies

Title:Signaling Pathways in Inflammation and Anti-inflammatory Therapies

Volume: 24 Issue: 14

Author(s): Yiu To Yeung, Faisal Aziz, Angelica Guerrero-Castilla and Sandro Arguelles*

Affiliation:

• Department of Physiology, Faculty of Pharmacy, University of Seville, Seville,Spain

Keywords: Inflammation, anti-inflammatory drug, p38 MAPK, IL-6, JAK/STAT, PI3K, hippo pathway.

Abstract: During the past decade, an abundance of new evidence highlighted the importance of inflammation in the development of chronic pathologies such as neurodegeneration, cancer, diabetes, cardiovascular disease and inflammatory bowel disease. However, most of the current therapies do not address the underlying problem and better therapies are urgently needed. A growing number of researchers have discovered various signaling pathways that are associated with the initiation and progression of inflammation. Among different pathways, we will focus on three classical inflammatory pathways: p38 MAPK, IL-6/JAK/STAT3 and PI3K; and a non-classical inflammatory pathway, the Hippo. Recently, the Hippo pathway has been linked to various inflammatory modulators such as FoxO1/3, TNFα, IL-6, COX2, HIF-1α, AP-1, JAK and STAT. In this review, the molecular mechanisms, associated pathologies and selected drugs (both preclinical and clinical) of these signaling pathways will be summarized. Finally, limitations and potential risks of anti-inflammatory drugs will also be discussed.

Cite this article as:

Yeung To Yiu , Aziz Faisal, Guerrero-Castilla Angelica and Arguelles Sandro *, Signaling Pathways in Inflammation and Anti-inflammatory Therapies, Current Pharmaceutical Design 2018; 24 (14) . https://dx.doi.org/10.2174/1381612824666180327165604